Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $836.48

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-six ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, seventeen have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $836.48.

REGN has been the subject of several research analyst reports. Bank of America lowered their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a research note on Monday, June 2nd. Finally, BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research report on Monday, June 2nd.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after buying an additional 1,390,534 shares in the last quarter. Norges Bank purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $802,036,000. GAMMA Investing LLC boosted its stake in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $343,764,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 0.6%

REGN stock traded up $3.24 during midday trading on Thursday, hitting $521.84. 873,171 shares of the company's stock were exchanged, compared to its average volume of 873,023. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $1,211.20. The firm has a 50 day moving average price of $564.76 and a 200-day moving average price of $653.10. The stock has a market capitalization of $56.34 billion, a price-to-earnings ratio of 13.63, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter last year, the firm posted $9.55 EPS. The firm's quarterly revenue was down 3.7% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.